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Future therapies for diseases associated with altered dopaminergic signaling, 
including Parkinson’s disease, schizophrenia and drug addiction or drug 
dependence, may be substantially built on the existence of intramembrane receptor-
receptor interactions within receptor mosaics where it is believed that the D2
receptor may operate as the “hub receptor” [1]. In particular, it has been proposed 
that striatal dopaminergic neurotransmission could be under the control of  receptor 
heteromers containing D2 autoreceptors and non-?7 nicotinic acetylcholine 
heteroreceptors [2]. 
In an attempt to investigate the biochemical and functional interactions 
between dopaminergic autoreceptors and nAChRs containing the ?2 subunit, we 
designed and prepared a group of potential bifunctional derivatives incorporating a
D2/D3 agonist moiety and a nicotinic ?4?2 antagonist fragment, linked by 
polymethylene spacers of different length. 
The new compounds have been biologically characterized for their 
affinity/specificity/functional profile at the target nACh and D2 receptor subtypes. 
The synthesis of the designed derivatives and the results of their pharmacological 
investigation will be presented and discussed. 
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